Treatment of A549 tumor-bearing mice with CA (20 and 40 mg/kg) meaningfully reduced the tumor volume, decreased TNF-α, IL-6, and IL-1β, p-NF-κBp65, and increased Nrf2 and HO-1 in the comparison control group [146]. This evidence concerns the gene NFE2L2 and neoplasm.